Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
ONTARGET - Ongoing telmisartan alone and in combination with ramipril global endpoint trial und TRANSCEND - Telmisartan randomized assessment study in ACE-I intolerant subjects with cardiovascular disease (30 Abbildungen)
Übersicht
Gesamtpräsentation zum Download (rechte Maustaste und "Ziel speichern unter..." klicken)


Zum ersten Bild Abb. 9: HOPE study results: secondary end point Abb. 10: ONTARGET - Rationale Abb. 11: ONTARGET - rationale Aktuelles Bild - Abb. 12: ONTARGET - rationale Abb. 13: ONTARGET - objectives Abb. 14: ONTARGET - a global trial Abb. 15: ONTARGET - participating countries Zum letzten Bild
Abbildung 12: ONTARGET - rationale
Treatment of patients at high risk of cardiovascular complications with a combination of telmisartan and ramipril has a three-fold rationale: AT1 receptor blockade by telmisartan should avert the negative consequences of angiotensin II escape associated with ramipril monotherapy treatment. Due to the selectivity of telmisartan for the AT1 receptors, any excess angiotensin II will only act at the AT2 receptors. Stimulation of AT2 receptors appears to be associated with beneficial effects. The potential tissue-protective properties associated with increased plasma bradykinin levels will be preserved.
 
ONTARGET - rationale
Vorheriges Bild Nächstes Bild   


Abbildung 12: ONTARGET - rationale
Treatment of patients at high risk of cardiovascular complications with a combination of telmisartan and ramipril has a three-fold rationale: AT1 receptor blockade by telmisartan should avert the negative consequences of angiotensin II escape associated with ramipril monotherapy treatment. Due to the selectivity of telmisartan for the AT1 receptors, any excess angiotensin II will only act at the AT2 receptors. Stimulation of AT2 receptors appears to be associated with beneficial effects. The potential tissue-protective properties associated with increased plasma bradykinin levels will be preserved.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung